Table 3.
Detailed characteristics of the MM patients (n = 14)
| Patients | Histological subtype and previous treatment |
Stage, Site, Side |
Age at molecular profiling and gender | Detected mutations by NGS | IHC | FiSH |
Therapy recommendation and response |
|---|---|---|---|---|---|---|---|
| 1 |
Epitheloid multimodality treatment |
IV°, Pleura, Left |
34 years, Female |
No mutation detected | Not done (due to insufficient tissue material) | Not done (due to insufficient tissue material) | No recommendation |
| 2 |
Epitheloid multimodality treatment |
IV°, Pleura, Right |
74 years, Male |
TP53 (exon 5) |
EGFR 3+, MET 3+, PDGFRa 1+, PDGFRb 1+, TPS PD‐L1 ≥ 50%, p‐mTOR 1+, PTEN 1+ |
No alteration | Pembrolizumab |
| 3 |
Epitheloid multimodality treatment |
IV°, Pleura, Right |
49 years, Male |
SRC (exon 9) |
EGFR 3+, MET 3+, PDGFRa 1+, PTEN 1+, p‐mTOR 2+ |
No alteration | Dasatinib |
| 4 | Epitheloid |
IV°, Pleura, Left |
48 years, Male |
No mutation detected |
EGFR 3+, MET 1+, PDGFRa 1+, PTEN 1+, p‐mTOR 1+ |
No alteration | Cetuximab |
| 5 | Epitheloid |
IV°, Pleura, Right |
41 years, Male |
No mutation detected |
EGFR 2+, MET 2+, TPS PD‐L1 ≥ 50%, p‐mTOR 2+, PTEN 1+ |
No alteration | Pembrolizumab |
| 6 | Epitheloid |
IV°, Pleura, Left |
59 years, Male |
No mutation detected |
EGFR 1+, PDGFRa 1+, PDGFRb 1+, p‐mTOR 1+, PTEN 1+ |
No alteration | Sunitinib |
| 7 | Epitheloid |
IV°, Pleura, Right |
59 years, Male |
No mutation detected |
EGFR 2+, PDGFRa 1+, PDGFRb 2+, PTEN 1+ |
No alteration | Sunitinib |
| 8 |
Epitheloid multimodality treatment |
IV°, Pleura, Left |
58 years, Male |
No mutation detected |
EGFR 3+, MET 3+, PDGFRa 2+, PTEN 1+, p‐mTOR 2+ |
No alteration | Cetuximab |
| 9 | Epitheloid |
IV°, Pleura, Right |
56 years, Female |
No mutation detected |
EGFR 3+, PDGFRb 1+, p‐mTOR 2+, PTEN 2+ |
No alteration | Cetuximab |
| 10 |
Epitheloid multimodality treatment |
IV°, Pleura, Right |
57 years, Male |
NF2 (exon 4), PD‐L1 (exon 5) |
EGFR 2+, TPS PD‐L1 ≥ 50%, p‐mTOR 1+ |
No alteration | Pembrolizumab |
| 11 | Epitheloid |
IV°, Pleura, Right |
37 years, Female |
FANCA (exon 40), NF1 (exon 17), RAD51D (exon 5) |
EGFR 3+, p‐mTOR 2+, PTEN 2+ |
No alteration | No recommendation |
| 12 | Epitheloid |
IV° Peritoneum, Right |
66 years, Male |
No mutation detected |
EGFR 3+, MET 2+, p‐mTOR 3+, PTEN+2 |
No alteration |
Nintedanib Patient achieved stable disease for 3 months |
| 13 | Epitheloid |
IV° Peritoneum, Right |
48 years, Female |
TP53 (exon 5) |
MET 2+, p‐mTOR 2+, Loss of PTEN |
Loss of PTEN | Everolimus |
| 14 | Biphasic |
IV° Peritoneum, Right |
48 years, Female |
BAP1 (exon 14), SETD2 (exon 3), NF2 (exon 6) |
EGFR 3+, p‐mTOR 3+, PTEN 2+ |
No alteration | No recommendation |
BAP1, BRCA1 associated protein‐1; EGFR, epidermal growth factor receptor; FANCA, Fanconi anemia, complementation group A; FiSH: fluorescence in situ hybridization; NF, neurofibromin; PDGFR, platelet‐derived growth factor receptor; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1; p‐mTOR, phosphorylated mammalian target of rapamycin; PTEN, phosphatase and tensin homolog; TP53, tumor protein 53; IHC, immunohistochemistry; NGS, next‐generation sequencing; SETD2, SET domain containing 2, TPS, tumor proportion score.